Niharika B. Mettu, Ph.D.
Affiliations: | 2007 | Duke University, Durham, NC |
Area:
Molecular BiologyGoogle:
"Niharika Mettu"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Donald P. McDonnell | grad student | 2007 | Duke | |
| (Targeting the coactivator interaction surface as a mechanism of regulating nuclear receptor transcriptional activity.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Overman M, Javle M, Davis RE, et al. (2020) Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Journal For Immunotherapy of Cancer. 8 |
| Gutierrez M, Subbiah V, Nemunaitis JJ, et al. (2020) Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study. Journal of Clinical Oncology. 38: 3606-3606 |
| Subbiah V, Barve M, Iannotti NO, et al. (2019) Abstract A078: FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies Molecular Cancer Therapeutics. 18 |
| Mettu NB, Niedzwiecki D, Boland PM, et al. (2018) BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer. Journal of Clinical Oncology. 36: TPS873-TPS873 |
| Mettu NB, Stanley TB, Dwyer MA, et al. (2007) The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. Molecular Endocrinology (Baltimore, Md.). 21: 2361-77 |